Journal article · 2023 · Open access
Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer
PLoS ONE, 18(1), e0280259 · Published 17 January 2023 · DOI 10.1371/journal.pone.0280259
In brief
“Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer” is a 2023 journal article by Emuella M. Flood and 9 co-authors, published in PLoS ONE. OpenAlex counts 6 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at PLoS ONE.
- Citations
- 6
- Most cited in
- 2025 (3)
- Field-weighted impact
- 0.66
- References
- 39
- Authors
- 10
Abstract
BACKGROUND: Designing clinical trials with the emphasis on the patient-centered approach and focusing on clinical outcomes that are meaningful to patients is viewed as a priority by drug developers, regulatory agencies, payers, clinicians, and patients. This study aimed to capture information on clinical trial endpoints that would be most important and relevant for patients with advanced breast cancer, based on patient-reported outcomes. METHODS: Patients with either advanced triple-negative breast cancer [TNBC] and a maximum of two lines of systemic therapy or hormone receptor-positive/human epidermal growth factor receptor 2-negative [HR+/HER2-] breast cancer and a maximum of three lines of systemic therapy, participated in semi-structured concept elicitation interviews. Concept saturation was assessed. A sign, symptom, or impact was defined as "salient" if mentioned by ≥ 60% of participants, with an average bother rating of ≥ 5 (0-10 Scale). Participants were also asked about treatment priorities and to evaluate hypothetical scenarios showing different health-related functioning and quality-of-life treatment outcomes, using graphical representations. RESULTS: Thirty-two participants (97% women; aged 29+ years) with TNBC (n = 17) or HR+/HER2- breast cancer (n = 15) provided generally similar reports on symptom experience, with fatigue and pain being most salient, though importance of certain treatment-related symptoms varied between the two groups. Patients reported consistent perspectives on the importance of treatment outcomes: when considering a new treatment, they prioritized efficacy of the therapy, acceptable tolerability, stability, predictability of symptoms over time, and the duration of preserved health-related quality of life and physical functioning. The meaningful difference in preserved physical functioning was 2-3 months for 46% of participants with TNBC, whereas for most participants with HR+/HER2- breast cancer it started from 6-7 months. Both groups of participants found it easier to accept some toxicity at the beginning of therapy if it was followed by improvement, as opposed to improvement followed by deterioration. CONCLUSION: The results may help to inform the design of patient-centered clinical trials, to interpret health-related quality of life and/or patient-reported outcomes, and to optimize care for patients with advanced breast cancer.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Flood, E. M., Krasnow, A. M., Orbegoso, C., Karantzoulis, S., Bailey, J. R., Bayet, S., Elghouayel, A. E., Foxley, A., Sommavilla, R., & Schiavon, G. (2023). Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer. PLoS ONE, 18(1), e0280259. https://doi.org/10.1371/journal.pone.0280259
MLA 9
Flood, Emuella M., et al. “Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer.” PLoS ONE, vol. 18, no. 1, 2023, p. e0280259. https://doi.org/10.1371/journal.pone.0280259.
Chicago
Flood, Emuella M., Anna M. Krasnow, Cecilia Orbegoso, Stella Karantzoulis, Julie R. Bailey, Solene Bayet, Arthur E. Elghouayel, Andrew Foxley, Roberto Sommavilla, and Gaia Schiavon. 2023. “Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer.” PLoS ONE 18 (1): e0280259. https://doi.org/10.1371/journal.pone.0280259.
Harvard
Flood, E. M. et al. (2023) ‘Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer’, PLoS ONE, 18(1), p. e0280259. doi:10.1371/journal.pone.0280259.
IEEE
E. M. Flood et al., “Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer,” PLoS ONE, vol. 18, no. 1, p. e0280259, 2023, doi: 10.1371/journal.pone.0280259.
BibTeX
@article{flood2023using,
title = {{Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer}},
author = {Flood, Emuella M. and Krasnow, Anna M. and Orbegoso, Cecilia and Karantzoulis, Stella and Bailey, Julie R. and Bayet, Solene and Elghouayel, Arthur E. and Foxley, Andrew and Sommavilla, Roberto and Schiavon, Gaia},
journal = {PLoS ONE},
year = {2023},
volume = {18},
number = {1},
pages = {e0280259},
doi = {10.1371/journal.pone.0280259},
url = {https://doi.org/10.1371/journal.pone.0280259}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 1 | |
| 2024 | 1 | |
| 2025 | 3 | |
| 2026 | 1 |
Its field-weighted citation impact is 0.66: it has been cited 0.66 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer survivorship and care
- advanced breast cancer
- patient-reported outcomes
- clinical trial endpoints
- triple-negative breast cancer
- hormone receptor-positive HER2-negative breast cancer
- concept elicitation interviews
- symptom burden
- fatigue
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Flood, E. M., Krasnow, A. M., Orbegoso, C., Karantzoulis, S., Bailey, J. R., Bayet, S., Elghouayel, A. E., Foxley, A., Sommavilla, R., & Schiavon, G. (2023). Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer. PLoS ONE, 18(1), e0280259. https://doi.org/10.1371/journal.pone.0280259
How many times has this paper been cited?
6 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PLoS ONE: sign in and open the PDF from this page.
Who wrote this paper?
Emuella M. Flood, Anna M. Krasnow, Cecilia Orbegoso, Stella Karantzoulis, Julie R. Bailey, Solene Bayet, Arthur E. Elghouayel, Andrew Foxley, Roberto Sommavilla, Gaia Schiavon.
What is the DOI of this paper?
10.1371/journal.pone.0280259, permanently at https://doi.org/10.1371/journal.pone.0280259. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.